{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T05:26:48Z","timestamp":1793683608595,"version":"4.5.1"},"reference-count":164,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270622"],"award-info":[{"award-number":["82270622"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470627"],"award-info":[{"award-number":["82470627"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370600"],"award-info":[{"award-number":["82370600"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajp.amjpathol.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Pathology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ajpath.2026.09.004","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T06:58:33Z","timestamp":1790319513000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Gut\u2013Liver Axis in Metabolic Dysfunction\u2013Associated Steatotic Liver Disease and Associated Hepatocellular Carcinoma"],"prefix":"10.1016","author":[{"given":"Qian","family":"Huai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2605-5697","authenticated-orcid":false,"given":"Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0841-8391","authenticated-orcid":false,"given":"Shi","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpath.2026.09.004_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ajpath.2026.09.004_bib2","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/s41575-023-00759-2","article-title":"Global epidemiology of cirrhosis--aetiology, trends and predictions","volume":"20","author":"Huang","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2026.09.004_bib3","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jhep.2021.08.012","article-title":"Epidemiology and risk-stratification of NAFLD-associated HCC","volume":"75","author":"Ioannou","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2026.09.004_bib4","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ajpath.2026.09.004_bib5","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2026.09.004_bib6","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2026.09.004_bib7","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2026.09.004_bib8","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1016\/j.cgh.2024.05.052","article-title":"Genetics of metabolic dysfunction-associated steatotic liver disease: the state of the art update","volume":"22","author":"Sookoian","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2026.09.004_bib9","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1038\/s41591-023-02553-8","article-title":"Interaction between estrogen receptor-[alpha] and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women","volume":"29","author":"Cherubini","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.ajpath.2026.09.004_bib10","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1172\/JCI86013","article-title":"Insulin receptor Thr1160 phosphorylation mediates lipid-induced hepatic insulin resistance","volume":"126","author":"Petersen","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ajpath.2026.09.004_bib11","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1053\/j.gastro.2013.11.049","article-title":"Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease","volume":"146","author":"Lambert","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajpath.2026.09.004_bib12","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","article-title":"The gut-liver axis in liver disease: pathophysiological basis for therapy","volume":"72","author":"Albillos","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2026.09.004_bib13","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nature24302","article-title":"Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity","volume":"551","author":"Shalapour","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2026.09.004_bib14","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nature16969","article-title":"NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis","volume":"531","author":"Ma","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2026.09.004_bib15","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41579-023-00904-3","article-title":"The gut-liver axis and gut microbiota in health and liver disease","volume":"21","author":"Hsu","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.ajpath.2026.09.004_bib16","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41575-018-0011-z","article-title":"The gut-liver axis and the intersection with the microbiome","volume":"15","author":"Tripathi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2026.09.004_bib17","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000310","article-title":"Gut microbiota and metabolic biomarkers in metabolic dysfunction-associated steatotic liver disease","volume":"8","author":"Long","year":"2024","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.ajpath.2026.09.004_bib18","article-title":"Changes in the intestinal microbiota of individuals with non-alcoholic fatty liver disease based on sequencing: an updated systematic review and meta-analysis","volume":"19","author":"Cai","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.ajpath.2026.09.004_bib19","article-title":"Intestinal Akkermansia muciniphila complements the efficacy of PD1 therapy in MAFLD-related hepatocellular carcinoma","volume":"6","author":"Wu","year":"2025","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.ajpath.2026.09.004_bib20","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41467-020-20422-7","article-title":"Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma","volume":"12","author":"Behary","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajpath.2026.09.004_bib21","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.cmet.2019.08.018","article-title":"Fatty liver disease caused by high-alcohol-producing Klebsiella pneumoniae","volume":"30","author":"Yuan","year":"2019","journal-title":"Cell Metab"},{"key":"10.1016\/j.ajpath.2026.09.004_bib22","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.cmet.2017.04.001","article-title":"Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease","volume":"25","author":"Loomba","year":"2017","journal-title":"Cell Metab"},{"key":"10.1016\/j.ajpath.2026.09.004_bib23","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13073-017-0490-5","article-title":"A novel Ruminococcus gnavus clade enriched in inflammatory bowel disease patients","volume":"9","author":"Hall","year":"2017","journal-title":"Genome Med"},{"key":"10.1016\/j.ajpath.2026.09.004_bib24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/hep.30036","article-title":"Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease","volume":"69","author":"Ponziani","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2026.09.004_bib25","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1053\/j.gastro.2019.06.028","article-title":"Microbiome signatures associated with steatohepatitis and moderate to severe fibrosis in children with nonalcoholic fatty liver disease","volume":"157","author":"Schwimmer","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajpath.2026.09.004_bib26","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nature13568","article-title":"Alterations of the human gut microbiome in liver cirrhosis","volume":"513","author":"Qin","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2026.09.004_bib27","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1136\/gutjnl-2017-315084","article-title":"Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma","volume":"68","author":"Ren","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.ajpath.2026.09.004_bib28","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/s42255-025-01318-6","article-title":"Multi-omic analysis reveals transkingdom gut dysbiosis in metabolic dysfunction-associated steatotic liver disease","volume":"7","author":"Kim","year":"2025","journal-title":"Nat Metab"},{"key":"10.1016\/j.ajpath.2026.09.004_bib29","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jhep.2021.11.029","article-title":"The fecal mycobiome in non-alcoholic fatty liver disease","volume":"76","author":"Demir","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2026.09.004_bib30","article-title":"Mycobiome dysbiosis and genetic predisposition for elevated IL-17A contribute to fibrosis in MASLD","volume":"8","author":"Thielemann","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1016\/j.ajpath.2026.09.004_bib31","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1053\/j.gastro.2020.07.005","article-title":"Intestinal virome signature associated with severity of nonalcoholic fatty liver disease","volume":"159","author":"Lang","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajpath.2026.09.004_bib32","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/nature09944","article-title":"Enterotypes of the human gut microbiome","volume":"473","author":"Arumugam","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2026.09.004_bib33","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1126\/science.aad0135","article-title":"A gut-vascular barrier controls the systemic dissemination of bacteria","volume":"350","author":"Spadoni","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ajpath.2026.09.004_bib34","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1111\/liv.14696","article-title":"Intestinal permeability in human nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"40","author":"De Munck","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.ajpath.2026.09.004_bib35","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/hep.31056","article-title":"Increased liver localization of lipopolysaccharides in human and experimental NAFLD","volume":"72","author":"Carpino","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2026.09.004_bib36","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/hep.22848","article-title":"Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease","volume":"49","author":"Miele","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2026.09.004_bib37","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe1692","article-title":"Hepatocyte TLR4 triggers inter-hepatocyte Jagged1\/Notch signaling to determine NASH-induced fibrosis","volume":"13","author":"Yu","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ajpath.2026.09.004_bib38","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.dld.2014.02.010","article-title":"Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity","volume":"46","author":"Giorgio","year":"2014","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.ajpath.2026.09.004_bib39","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1053\/j.gastro.2016.06.022","article-title":"Loss of junctional adhesion molecule A promotes severe steatohepatitis in mice on a diet high in saturated fat, fructose, and cholesterol","volume":"151","author":"Rahman","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajpath.2026.09.004_bib40","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/s41579-022-00805-x","article-title":"Bile acids and the gut microbiota: metabolic interactions and impacts on disease","volume":"21","author":"Collins","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.ajpath.2026.09.004_bib41","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/hep.28709","article-title":"Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives","volume":"65","author":"Arab","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2026.09.004_bib42","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1210\/er.2018-00134","article-title":"Fibroblast growth factor 15\/19: from basic functions to therapeutic perspectives","volume":"39","author":"Somm","year":"2018","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ajpath.2026.09.004_bib43","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1136\/gutjnl-2017-314307","article-title":"Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD","volume":"67","author":"Jiao","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.ajpath.2026.09.004_bib44","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/hep.32568","article-title":"Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD","volume":"76","author":"Smirnova","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2026.09.004_bib45","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1097\/HEP.0000000000000474","article-title":"An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations","volume":"78","author":"Carr","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2026.09.004_bib46","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nature12347","article-title":"Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome","volume":"499","author":"Yoshimoto","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2026.09.004_bib47","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.cmet.2023.07.011","article-title":"Hyodeoxycholic acid alleviates non-alcoholic fatty liver disease through modulating the gut-liver axis","volume":"35","author":"Kuang","year":"2023","journal-title":"Cell Metab"},{"key":"10.1016\/j.ajpath.2026.09.004_bib48","first-page":"763","article-title":"Akkermansia muciniphila and Bifidobacterium bifidum prevent NAFLD by regulating FXR expression and gut microbiota","volume":"11","author":"Nian","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.ajpath.2026.09.004_bib49","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41577-024-01014-8","article-title":"Short-chain fatty acids: linking diet, the microbiome and immunity","volume":"24","author":"Mann","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ajpath.2026.09.004_bib50","doi-asserted-by":"crossref","first-page":"16767","DOI":"10.1073\/pnas.0808567105","article-title":"Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41","volume":"105","author":"Samuel","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajpath.2026.09.004_bib51","doi-asserted-by":"crossref","first-page":"6734","DOI":"10.1038\/ncomms7734","article-title":"Metabolite-sensing receptors GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome","volume":"6","author":"Macia","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajpath.2026.09.004_bib52","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1038\/s41467-020-18262-6","article-title":"Intestinal microbiota-derived short-chain fatty acids regulation of immune cell IL-22 production and gut immunity","volume":"11","author":"Yang","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajpath.2026.09.004_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109332","article-title":"Gut microbiota-derived short-chain fatty acids regulate IL-17 production by mouse and human intestinal [gamma][delta] T cells","volume":"36","author":"Dupraz","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.ajpath.2026.09.004_bib54","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.immuni.2025.03.017","article-title":"Acute exposure to high-fat diet impairs ILC3 functions and gut homeostasis","volume":"58","author":"Xiong","year":"2025","journal-title":"Immunity"},{"key":"10.1016\/j.ajpath.2026.09.004_bib55","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1073\/pnas.1322269111","article-title":"The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition","volume":"111","author":"Chang","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajpath.2026.09.004_bib56","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000492853","article-title":"Short-chain fatty acids manifest stimulative and protective effects on intestinal barrier function through the inhibition of NLRP3 inflammasome and autophagy","volume":"49","author":"Feng","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.ajpath.2026.09.004_bib57","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41419-023-05853-6","article-title":"Butyrate limits inflammatory macrophage niche in NASH","volume":"14","author":"Sarkar","year":"2023","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.ajpath.2026.09.004_bib58","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.jhep.2023.07.005","article-title":"Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma","volume":"79","author":"Song","year":"2023","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.ajpath.2026.09.004_bib59","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/HEP.0000000000001446","article-title":"Distinct gut microbiota but common metabolomic signatures between viral and MASLD HCC contribute to outcomes of combination immunotherapy","volume":"84","author":"Lee","year":"2026","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2026.09.004_bib60","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hep.32449","article-title":"Gut microbiota-derived short-chain fatty acids regulate group 3 innate lymphoid cells in HCC","volume":"77","author":"Hu","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2026.09.004_bib61","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.apsb.2024.10.010","article-title":"Akkermansia muciniphila-derived acetate activates the hepatic AMPK\/SIRT1\/PGC-1[alpha] axis to alleviate ferroptosis in metabolic-associated fatty liver disease","volume":"15","author":"Zhuge","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.ajpath.2026.09.004_bib62","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.cell.2018.09.004","article-title":"Dysregulated microbial fermentation of soluble fiber induces cholestatic liver cancer","volume":"175","author":"Singh","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ajpath.2026.09.004_bib63","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12943-024-02164-y","article-title":"Molecular mechanisms and therapeutic significance of tryptophan metabolism and signaling in cancer","volume":"23","author":"Yan","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ajpath.2026.09.004_bib64","doi-asserted-by":"crossref","first-page":"174","DOI":"10.21037\/atm-20-3594","article-title":"A narrative review of the roles of indoleamine 2,3-dioxygenase and tryptophan-2,3-dioxygenase in liver diseases","volume":"9","author":"Zhou","year":"2021","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.ajpath.2026.09.004_bib65","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1038\/s41467-018-07287-7","article-title":"Serotonin signals through a gut-liver axis to regulate hepatic steatosis","volume":"9","author":"Choi","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajpath.2026.09.004_bib66","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41575-021-00430-8","article-title":"AHR in the intestinal microenvironment: safeguarding barrier function","volume":"18","author":"Stockinger","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2026.09.004_bib67","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41392-025-02500-8","article-title":"The aryl hydrocarbon receptor: structure, signaling, physiology and pathology","volume":"11","author":"Coumoul","year":"2026","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ajpath.2026.09.004_bib68","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.clnu.2024.04.008","article-title":"The role of the aryl hydrocarbon receptor (AhR) in modulating intestinal ILC3s to optimise gut pathogen resistance in lupus and benefits of nutritional AhR ligands","volume":"43","author":"Hanlon","year":"2024","journal-title":"Clin Nutr"},{"key":"10.1016\/j.ajpath.2026.09.004_bib69","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1136\/gutjnl-2020-323071","article-title":"Gut microbiota-derived metabolites as central regulators in metabolic disorders","volume":"70","author":"Agus","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.ajpath.2026.09.004_bib70","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00281-021-00867-8","article-title":"The aryl hydrocarbon receptor in liver inflammation","volume":"43","author":"Carambia","year":"2021","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.ajpath.2026.09.004_bib71","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2024.2307568","article-title":"Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation","volume":"16","author":"Min","year":"2024","journal-title":"Gut Microbes"},{"key":"10.1016\/j.ajpath.2026.09.004_bib72","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1038\/s41591-022-02016-6","article-title":"Microbiome-derived ethanol in nonalcoholic fatty liver disease","volume":"28","author":"Meijnikman","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ajpath.2026.09.004_bib73","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/s41575-023-00822-y","article-title":"The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease","volume":"20","author":"D\u00edaz","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2026.09.004_bib74","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.3390\/cells11213390","article-title":"Endogenous ethanol and triglyceride production by gut Pichia kudriavzevii, Candida albicans and Candida glabrata yeasts in non-alcoholic steatohepatitis","volume":"11","author":"Mbaye","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ajpath.2026.09.004_bib75","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/j.cmet.2025.09.001","article-title":"Catenibacterium mitsuokai promotes hepatocellular carcinogenesis by binding to hepatocytes and generating quinolinic acid","volume":"37","author":"Zhang","year":"2025","journal-title":"Cell Metab"},{"key":"10.1016\/j.ajpath.2026.09.004_bib76","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41564-024-01890-9","article-title":"Gut-liver translocation of pathogen Klebsiella pneumoniae promotes hepatocellular carcinoma in mice","volume":"10","author":"Wang","year":"2025","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.ajpath.2026.09.004_bib77","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3390\/metabo12121243","article-title":"Trimethylamine N-oxide levels in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"12","author":"Theofilis","year":"2022","journal-title":"Metabolites"},{"key":"10.1016\/j.ajpath.2026.09.004_bib78","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/j.cmet.2025.07.001","article-title":"Gut substrate trap of D-lactate from microbiota improves blood glucose and fatty liver disease in obese mice","volume":"37","author":"Fang","year":"2025","journal-title":"Cell Metab"},{"key":"10.1016\/j.ajpath.2026.09.004_bib79","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/hep4.1479","article-title":"Pathogenesis of nonalcoholic steatohepatitis: an overview","volume":"4","author":"Parthasarathy","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.ajpath.2026.09.004_bib80","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jhep.2017.11.014","article-title":"Lipotoxicity and the gut-liver axis in NASH pathogenesis","volume":"68","author":"Marra","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2026.09.004_bib81","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jcmgh.2023.08.001","article-title":"Escherichia coli promotes endothelial to mesenchymal transformation of liver sinusoidal endothelial cells and exacerbates nonalcoholic fatty liver disease via its flagellin","volume":"16","author":"Shen","year":"2023","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2026.09.004_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113173","article-title":"Gut microbiota metabolite trimethylamine N-oxide promoted NAFLD progression by exacerbating intestinal barrier disruption and intrahepatic cellular imbalance","volume":"142","author":"Nian","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.ajpath.2026.09.004_bib83","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s11605-021-05188-7","article-title":"The role of gut-derived lipopolysaccharides and the intestinal barrier in fatty liver diseases","volume":"26","author":"An","year":"2022","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.ajpath.2026.09.004_bib84","article-title":"A new insight: crosstalk between neutrophil extracellular traps and the gut-liver axis for nonalcoholic fatty liver disease","volume":"16","author":"Yin","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.ajpath.2026.09.004_bib85","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41575-019-0210-2","article-title":"Adaptive immunity: an emerging player in the progression of NAFLD","volume":"17","author":"Sutti","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2026.09.004_bib86","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1177\/2050640618804444","article-title":"Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease","volume":"6","author":"Rau","year":"2018","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.ajpath.2026.09.004_bib87","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4049\/jimmunol.1501175","article-title":"Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis is marked by a higher frequency of Th17 cells in the liver and an increased Th17\/resting regulatory T cell ratio in peripheral blood and in the liver","volume":"196","author":"Rau","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.ajpath.2026.09.004_bib88","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1158\/2159-8290.CD-16-0932","article-title":"Gut microbiota promotes obesity-associated liver cancer through PGE(2)-mediated suppression of antitumor immunity","volume":"7","author":"Loo","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ajpath.2026.09.004_bib89","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s11427-023-2634-7","article-title":"The gut microbiome modulate response to immunotherapy in cancer","volume":"68","author":"Jiang","year":"2025","journal-title":"Sci China Life Sci"},{"key":"10.1016\/j.ajpath.2026.09.004_bib90","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004779","article-title":"Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma","volume":"10","author":"Lee","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ajpath.2026.09.004_bib91","article-title":"Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma","volume":"5","author":"Pinato","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.ajpath.2026.09.004_bib92","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jhep.2020.11.024","article-title":"Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores","volume":"74","author":"Bianco","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2026.09.004_bib93","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/gutjnl-2024-332398","article-title":"Interplay between gut microbiome, host genetic and epigenetic modifications in MASLD and MASLD-related hepatocellular carcinoma","volume":"74","author":"Ha","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.ajpath.2026.09.004_bib94","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41392-023-01333-7","article-title":"Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study","volume":"8","author":"Wu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ajpath.2026.09.004_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103858","article-title":"The influence of host genetics on liver microbiome composition in patients with NAFLD","volume":"76","author":"Pirola","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ajpath.2026.09.004_bib96","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s42255-024-01177-7","article-title":"Intestinal TM6SF2 protects against metabolic dysfunction-associated steatohepatitis through the gut-liver axis","volume":"7","author":"Zhang","year":"2025","journal-title":"Nat Metab"},{"key":"10.1016\/j.ajpath.2026.09.004_bib97","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3390\/ijms27020566","article-title":"DNA methylation and its role in personalized nutrition: mechanisms, clinical insights, and future perspectives","volume":"27","author":"Hussain","year":"2026","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ajpath.2026.09.004_bib98","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2023.2223330","article-title":"Faecal microbiota transplantation affects liver DNA methylation in non-alcoholic fatty liver disease: a multi-omics approach","volume":"15","author":"Stols-Gon\u00e7alves","year":"2023","journal-title":"Gut Microbes"},{"key":"10.1016\/j.ajpath.2026.09.004_bib99","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/s41467-020-15126-x","article-title":"Impact of the gut microbiota on the m(6)A epitranscriptome of mouse cecum and liver","volume":"11","author":"Jabs","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajpath.2026.09.004_bib100","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/apt.12758","article-title":"Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis","volume":"39","author":"Alisi","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ajpath.2026.09.004_bib101","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1665-2681(19)31364-X","article-title":"Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study","volume":"12","author":"Wong","year":"2013","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.ajpath.2026.09.004_bib102","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12967-025-07478-z","article-title":"The effects of next generation probiotics on metabolic dysfunction-associated steatotic liver disease: a parallel, double-blind, randomized, placebo-controlled trial","volume":"24","author":"Won","year":"2025","journal-title":"J Transl Med"},{"key":"10.1016\/j.ajpath.2026.09.004_bib103","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/j.tjnut.2023.05.019","article-title":"Probiotic supplementation, hepatic fibrosis, and the microbiota profile in patients with nonalcoholic steatohepatitis: a randomized controlled trial","volume":"153","author":"Escouto","year":"2023","journal-title":"J Nutr"},{"key":"10.1016\/j.ajpath.2026.09.004_bib104","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1186\/s12876-024-03424-3","article-title":"The effect of probiotic supplementation on non-alcoholic fatty liver disease (NAFLD) fibrosis score in patients attending a tertiary hospital clinic in Cairo, Egypt","volume":"24","author":"Abd El Hamid","year":"2024","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.ajpath.2026.09.004_bib105","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00394-018-1721-2","article-title":"Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial","volume":"58","author":"Bomhof","year":"2019","journal-title":"Eur J Nutr"},{"key":"10.1016\/j.ajpath.2026.09.004_bib106","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.cmet.2023.08.002","article-title":"Resistant starch decreases intrahepatic triglycerides in patients with NAFLD via gut microbiome alterations","volume":"35","author":"Ni","year":"2023","journal-title":"Cell Metab"},{"key":"10.1016\/j.ajpath.2026.09.004_bib107","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1016\/j.cmet.2025.10.017","article-title":"Interindividual variability in gut microbiome mediates the efficacy of resistant starch on MASLD","volume":"37","author":"Long","year":"2025","journal-title":"Cell Metab"},{"key":"10.1016\/j.ajpath.2026.09.004_bib108","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s00394-025-03660-7","article-title":"Effects of combined prebiotic fiber supplementation and weight loss counseling in adults with metabolic dysfunction-associated steatotic liver disease: a randomized controlled trial","volume":"64","author":"Mayengbam","year":"2025","journal-title":"Eur J Nutr"},{"key":"10.1016\/j.ajpath.2026.09.004_bib109","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1053\/j.gastro.2020.01.031","article-title":"Synbiotics alter fecal microbiomes, but not liver fat or fibrosis, in a randomized trial of patients with nonalcoholic fatty liver disease","volume":"158","author":"Scorletti","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajpath.2026.09.004_bib110","first-page":"184","article-title":"The effects of synbiotics on the liver steatosis, inflammation, and gut microbiome of metabolic dysfunction-associated liver disease patients-randomized trial","volume":"62","author":"Mitrovi\u0107","year":"2024","journal-title":"Rom J Intern Med"},{"key":"10.1016\/j.ajpath.2026.09.004_bib111","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.14309\/ajg.0000000000000661","article-title":"Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: a randomized control trial","volume":"115","author":"Craven","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ajpath.2026.09.004_bib112","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.759306","article-title":"Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: a randomized clinical trial","volume":"12","author":"Xue","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.ajpath.2026.09.004_bib113","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2025.2541035","article-title":"Consecutive fecal microbiota transplantation for metabolic dysfunction-associated steatotic liver disease: a randomized controlled trial","volume":"17","author":"Groenewegen","year":"2025","journal-title":"Gut Microbes"},{"key":"10.1016\/j.ajpath.2026.09.004_bib114","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jhep.2010.08.030","article-title":"A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis","volume":"54","author":"Ratziu","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2026.09.004_bib115","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3748\/wjg.v27.i10.959","article-title":"Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease","volume":"27","author":"Nadinskaia","year":"2021","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ajpath.2026.09.004_bib116","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1136\/gutjnl-2014-308778","article-title":"Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology","volume":"65","author":"Dao","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.ajpath.2026.09.004_bib117","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-019-0495-2","article-title":"Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study","volume":"25","author":"Depommier","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.ajpath.2026.09.004_bib118","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nm.4236","article-title":"A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice","volume":"23","author":"Plovier","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.ajpath.2026.09.004_bib119","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11684-022-0960-z","article-title":"Role of Akkermansia muciniphila in the development of nonalcoholic fatty liver disease: current knowledge and perspectives","volume":"16","author":"Han","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.ajpath.2026.09.004_bib120","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2025.2612580","article-title":"Akkermansia muciniphila modulates intestinal mucus composition to counteract high-fat diet-induced obesity in mice","volume":"18","author":"Paone","year":"2026","journal-title":"Gut Microbes"},{"key":"10.1016\/j.ajpath.2026.09.004_bib121","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1038\/s41467-025-58500-3","article-title":"The carotenoid torularhodin alleviates NAFLD by promoting Akkermanisa muniniphila-mediated adenosylcobalamin metabolism","volume":"16","author":"Liu","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajpath.2026.09.004_bib122","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1136\/gutjnl-2025-336617","article-title":"Novel myo-inositol to butyrate fermentation pathway in the prevalent human gut species Dysosmobacter welbionis, a bacterium associated with improved metabolic and liver health","volume":"75","author":"Lee","year":"2026","journal-title":"Gut"},{"key":"10.1016\/j.ajpath.2026.09.004_bib123","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2024.2302065","article-title":"Prophylactic treatment with Bacteroides uniformis and Bifidobacterium bifidum counteracts hepatic NK cell immune tolerance in nonalcoholic steatohepatitis induced by high fat diet","volume":"16","author":"Xu","year":"2024","journal-title":"Gut Microbes"},{"key":"10.1016\/j.ajpath.2026.09.004_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117156","article-title":"Bacteroides ovatus alleviates high-fat and high-cholesterol -induced nonalcoholic fatty liver disease via gut-liver axis","volume":"178","author":"Sun","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.ajpath.2026.09.004_bib125","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1038\/s41564-023-01418-7","article-title":"Parabacteroides distasonis uses dietary inulin to suppress NASH via its metabolite pentadecanoic acid","volume":"8","author":"Wei","year":"2023","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.ajpath.2026.09.004_bib126","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1111\/jgh.16256","article-title":"Use of probiotics, prebiotics, and synbiotics in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"38","author":"Rong","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2026.09.004_bib127","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.clnu.2024.04.004","article-title":"Optimal probiotic combinations for treating nonalcoholic fatty liver disease: a systematic review and network meta-analysis","volume":"43","author":"Yang","year":"2024","journal-title":"Clin Nutr"},{"key":"10.1016\/j.ajpath.2026.09.004_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.jnutbio.2023.109546","article-title":"The synbiotic combination of probiotics and inulin improves NAFLD though modulating gut microbiota","volume":"125","author":"Zhang","year":"2024","journal-title":"J Nutr Biochem"},{"key":"10.1016\/j.ajpath.2026.09.004_bib129","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/apt.15416","article-title":"Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease","volume":"50","author":"Koopman","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ajpath.2026.09.004_bib130","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.jhep.2021.12.003","article-title":"Promises of microbiome-based therapies","volume":"76","author":"Bajaj","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2026.09.004_bib131","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41598-017-01751-y","article-title":"Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajpath.2026.09.004_bib132","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/hep4.1601","article-title":"Donor fecal microbiota transplantation alters gut microbiota and metabolites in obese individuals with steatohepatitis","volume":"4","author":"Witjes","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.ajpath.2026.09.004_bib133","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1053\/j.gastro.2012.06.031","article-title":"Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome","volume":"143","author":"Vrieze","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajpath.2026.09.004_bib134","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003051","article-title":"Fecal microbiota transplantation for the improvement of metabolism in obesity: The FMT-TRIM double-blind placebo-controlled pilot trial","volume":"17","author":"Yu","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.ajpath.2026.09.004_bib135","doi-asserted-by":"crossref","first-page":"G711","DOI":"10.1152\/ajpgi.00171.2024","article-title":"Fecal microbial transplants as investigative tools in cancer","volume":"327","author":"Bohm","year":"2024","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.ajpath.2026.09.004_bib136","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2023.2240031","article-title":"Unveiling the complex relationship between gut microbiota and liver cancer: opportunities for novel therapeutic interventions","volume":"15","author":"Rajapakse","year":"2023","journal-title":"Gut Microbes"},{"key":"10.1016\/j.ajpath.2026.09.004_bib137","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02828-24","article-title":"Oral delivery of GLP-1 peptide using recombinant Lactobacillus gasseri for the treatment of type 2 diabetes mellitus","volume":"13","author":"Ke","year":"2025","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.ajpath.2026.09.004_bib138","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/oby.22700","article-title":"Genetically engineered Escherichia coli Nissle 1917 secreting GLP-1 analog exhibits potential antiobesity effect in high-fat diet-induced obesity mice","volume":"28","author":"Ma","year":"2020","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.ajpath.2026.09.004_bib139","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00183-20","article-title":"Secretion of recombinant interleukin-22 by engineered Lactobacillus reuteri reduces fatty liver disease in a mouse model of diet-induced obesity","volume":"5","author":"Oh","year":"2020","journal-title":"mSphere"},{"key":"10.1016\/j.ajpath.2026.09.004_bib140","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2206744119","article-title":"CRISPR-based engineering of phages for in situ bacterial base editing","volume":"119","author":"Nethery","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajpath.2026.09.004_bib141","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1038\/s41467-023-39028-w","article-title":"Bacteriophage targeting microbiota alleviates non-alcoholic fatty liver disease induced by high alcohol-producing Klebsiella pneumoniae","volume":"14","author":"Gan","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajpath.2026.09.004_bib142","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.jhep.2021.08.003","article-title":"Intestinal virome and therapeutic potential of bacteriophages in liver disease","volume":"75","author":"Hsu","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2026.09.004_bib143","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0051017","article-title":"Synergistic action of gentamicin and bacteriophage in a continuous culture population of Staphylococcus aureus","volume":"7","author":"Kirby","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ajpath.2026.09.004_bib144","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.cell.2015.11.055","article-title":"Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis","volume":"163","author":"Wang","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ajpath.2026.09.004_bib145","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/HEP.0000000000000985","article-title":"Intestinal IL-33 promotes microbiota-derived trimethylamine N -oxide synthesis and drives metabolic dysfunction-associated steatotic liver disease progression by exerting dual regulation on HIF-1\u03b1","volume":"82","author":"Hai","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2026.09.004_bib146","doi-asserted-by":"crossref","first-page":"28","DOI":"10.20517\/mrr.2025.12","article-title":"Bile salt hydrolase: a key player in gut microbiota and its implications for metabolic dysfunction-associated steatotic liver disease","volume":"4","author":"Zhao","year":"2025","journal-title":"Microbiome Res Rep"},{"key":"10.1016\/j.ajpath.2026.09.004_bib147","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2025.2608437","article-title":"Bile salt hydrolase activity as a rational target for MASLD therapy","volume":"18","author":"Jones","year":"2026","journal-title":"Gut Microbes"},{"key":"10.1016\/j.ajpath.2026.09.004_bib148","doi-asserted-by":"crossref","DOI":"10.1136\/egastro-2025-100227","article-title":"Ursodeoxycholic acid acts as an ileal FXR agonist in male mice with hepatic deficiency of FXR","volume":"3","author":"Henry","year":"2025","journal-title":"eGastroenterology"},{"issue":"5","key":"10.1016\/j.ajpath.2026.09.004_bib149","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.jhep.2025.12.029","article-title":"AF6 knockout-induced upregulation of bile acid production promotes CXCL14-mediated antitumor immunity in HCC","volume":"84","author":"Xu","year":"2026","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2026.09.004_bib150","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41522-023-00451-y","article-title":"Inulin-enriched Megamonas funiformis ameliorates metabolic dysfunction-associated fatty liver disease by producing propionic acid","volume":"9","author":"Yang","year":"2023","journal-title":"NPJ Biofilms Microbiomes"},{"key":"10.1016\/j.ajpath.2026.09.004_bib151","doi-asserted-by":"crossref","DOI":"10.1016\/j.jnutbio.2022.109041","article-title":"Indole supplementation ameliorates MCD-induced NASH in mice","volume":"107","author":"Zhu","year":"2022","journal-title":"J Nutr Biochem"},{"key":"10.1016\/j.ajpath.2026.09.004_bib152","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/hep.31115","article-title":"Indole alleviates diet-induced hepatic steatosis and inflammation in a manner involving myeloid cell 6-phosphofructo-2-kinase\/fructose-2,6-biphosphatase 3","volume":"72","author":"Ma","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2026.09.004_bib153","doi-asserted-by":"crossref","DOI":"10.1126\/science.adp5540","article-title":"A symbiotic filamentous gut fungus ameliorates MASH via a secondary metabolite-CerS6-ceramide axis","volume":"388","author":"Zhou","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.ajpath.2026.09.004_bib154","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41579-023-00998-9","article-title":"Utilization of the microbiome in personalized medicine","volume":"22","author":"Ratiner","year":"2024","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.ajpath.2026.09.004_bib155","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/hep.28356","article-title":"The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota","volume":"63","author":"Boursier","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2026.09.004_bib156","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2023.2226922","article-title":"Targeting nonalcoholic fatty liver disease via gut microbiome-centered therapies","volume":"15","author":"Koning","year":"2023","journal-title":"Gut Microbes"},{"key":"10.1016\/j.ajpath.2026.09.004_bib157","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/aps.2014.116","article-title":"Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis","volume":"36","author":"Jiao","year":"2015","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.ajpath.2026.09.004_bib158","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ajpath.2026.09.004_bib159","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ajpath.2026.09.004_bib160","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.jhep.2019.08.005","article-title":"Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development","volume":"71","author":"Mouries","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2026.09.004_bib161","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.1038\/s41467-020-18754-5","article-title":"Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD","volume":"11","author":"Lee","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajpath.2026.09.004_bib162","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jhep.2021.10.013","article-title":"Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease","volume":"76","author":"Luukkonen","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2026.09.004_bib163","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jhep.2021.07.025","article-title":"Prevention of NAFLD-associated HCC: role of lifestyle and chemoprevention","volume":"75","author":"Lange","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2026.09.004_bib164","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41575-021-00472-y","article-title":"Dietary carbohydrates and fats in nonalcoholic fatty liver disease","volume":"18","author":"Yki-J\u00e4rvinen","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"}],"container-title":["The American Journal of Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944026002828?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944026002828?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:45:37Z","timestamp":1793681137000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002944026002828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":164,"alternative-id":["S0002944026002828"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpath.2026.09.004","relation":{},"ISSN":["0002-9440"],"issn-type":[{"value":"0002-9440","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Gut\u2013Liver Axis in Metabolic Dysfunction\u2013Associated Steatotic Liver Disease and Associated Hepatocellular Carcinoma","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpath.2026.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Investigative Pathology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}